Shenzhen Hornetcorn Bio-technology Company, LTD Report issue

For profit Phase 1 Phase 2
Founded: Shenzhen China (2010)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2014
NCT02202928
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cartilage Diseases (Phase 1)

Cerebral Hemorrhage (Phase 1)

Colorectal Neoplasms (Phase 2)

Digestive System Diseases (Phase 2)

Digestive System Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fibrosis (Phase 1)

Gastrointestinal Diseases (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Hemorrhage (Phase 1)

Intestinal Neoplasms (Phase 2)

Liver Cirrhosis (Phase 1)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Osteoarthritis (Phase 1)

Pneumoconiosis (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 8